Financial Performance - The company's revenue for Q1 2024 reached ¥1,280,469,171.09, representing a 46.06% increase compared to ¥876,697,159.06 in the same period last year[6] - Net profit attributable to shareholders was ¥19,436,945.89, up 27.14% from ¥15,287,632.67 year-on-year[6] - Net profit for Q1 2024 was ¥22,059,938.81, representing a 16% increase from ¥18,898,654.75 in Q1 2023[31] - Total operating revenue for Q1 2024 reached ¥1,280,469,171.09, a significant increase of 46% compared to ¥876,697,159.06 in the same period last year[29] - Total operating costs for Q1 2024 were ¥1,248,476,553.31, which is a 48% increase from ¥843,561,238.37 in Q1 2023[29] - The company reported a basic earnings per share of ¥0.09, compared to ¥0.07 in the same quarter last year, indicating a 28.6% increase[32] Cash Flow and Liquidity - The net cash flow from operating activities was -¥175,488,409.39, a decline of 87.40% compared to -¥93,644,192.00 in the previous year[6] - Cash flow from operating activities showed a net outflow of ¥175,488,409.39, worsening from a net outflow of ¥93,644,192.00 in Q1 2023[34] - The company's cash and cash equivalents decreased to RMB 392,530,769.23 from RMB 649,399,091.38, reflecting a decline of about 39.5%[24] - The ending balance of cash and cash equivalents was 354,815,404.93 CNY, down from 437,643,887.18 CNY year-over-year, indicating a decrease in liquidity[37] - The initial cash and cash equivalents balance was 617,317,750.46 CNY, compared to 520,743,935.35 CNY in the previous year, indicating a stronger starting liquidity position[37] Assets and Liabilities - Total assets increased by 14.59% to ¥6,047,540,005.59 from ¥5,277,655,319.75 at the end of the previous year[6] - The company's total liabilities increased to ¥4,214,968,157.10, up from ¥3,496,005,825.13, marking a growth of approximately 20.5% year-over-year[28] - The total current liabilities increased, with accounts payable rising to RMB 531,504,320.55 from RMB 402,725,045.60, an increase of about 32%[26] - Short-term borrowings rose by 9.87% to ¥1,671,646,157.03, driven by loans related to recent acquisitions[11] - The company's long-term borrowings increased to ¥1,133,800,123.89, up from ¥833,747,035.01, representing a growth of approximately 36%[28] Investments and Research - Research and development expenses surged by 186.31% to ¥2,061,921.04, primarily due to follow-up investments in newly acquired units[12] - Research and development expenses rose to ¥2,061,921.04, which is a 186% increase compared to ¥720,168.56 in the previous year[29] - The company experienced a 120.39% increase in net cash flow from investing activities, amounting to -¥425,988,313.13, attributed to investments in equity of other companies[14] - Cash paid for investment activities totaled 426,013,308.13 CNY, significantly higher than 209,292,390.70 CNY in the prior year, indicating aggressive investment strategies[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,430[16] - The company plans to issue 1.26 million shares of restricted stock and 2.94 million stock options to 33 incentive targets as part of its employee incentive program[21] - The company has approved a proposal for a specific stock issuance plan for 2024, which is expected to enhance its capital structure and support future growth initiatives[22] - The company has not reported any changes in the number of restricted shares for major shareholders during the period[19] Goodwill and Inventory - The goodwill on the balance sheet increased significantly to RMB 1,052,835,774.91 from RMB 717,930,711.43, reflecting a rise of approximately 46.6%[26] - The company reported a significant increase in inventory by 33.51% to ¥839,927,786.20 due to newly acquired enterprises[11] - Inventory rose to RMB 839,927,786.20 from RMB 629,106,306.73, indicating a growth of around 33.4%[26] - Accounts receivable increased to RMB 1,711,137,728.19 from RMB 1,565,646,271.02, marking an increase of approximately 9.3%[25] Financing Activities - Total cash inflow from financing activities was 741,000,000.00 CNY, up from 449,951,126.73 CNY year-over-year, reflecting a strong financing position[36] - The net cash flow from financing activities was 338,974,376.99 CNY, compared to 203,836,534.53 CNY in the same period last year, showing improved cash generation from financing[36] - The company received 720,000,000.00 CNY in borrowings during the quarter, compared to 398,000,000.00 CNY in the previous year, highlighting increased leverage[36] - Cash received from sales of goods and services was ¥1,188,214,685.67, an increase of 45% from ¥816,248,755.94 in the previous year[34] Audit and Reliability - The first quarter report was not audited, which may affect the reliability of the financial data presented[38]

国金证券股份有限公司 关于湖南达嘉维康医药产业股份有限公司 2023 年度定期现场检查报告 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有 关法律法规的要求，国金证券股份有限公司作为湖南达嘉维康医药产业股份有限 公司（以下简称"达嘉维康"或"公司"）持续督导之保荐机构，于 2024 年 4 月 18 日对达嘉维康有关情况进行了定期现场检查，报告如下： | 保荐人名称：国金证券股份有限公司 | 被保荐公司简称：达嘉维康 | | | | | | --- | --- | --- | --- | --- | --- | | 保荐代表人姓名：柳泰川 | 联系电话：021-68826801 | | | | | | 保荐代表人姓名：朱国民 | 联系电话：021-68826801 | | | | | | 现场检查人员姓名：朱国民 | | | | | | | 现场检查对应期间：2023 | 年度 | | | | | | 现场检查时间：2024 | 年 | 月 | 日 | 4 | 18 | | 一、现场检查事项 | 现场检查意见 | | | | | | （一）公司治理 | 是 | 否 | 不适用 | 现场 ...

湖南达嘉维康医药产业股份有限公司 2023 年度独立董事述职报告 （刘曙萍） 本人作为湖南达嘉维康医药产业股份有限公司（以下简称"公司"）的独立董事， 在 2023 年严格按照《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所创 业板股票上市规则》《公司章程》《独立董事工作制度》的规定，忠实、勤勉地履行了独 立董事的职责，谨慎、认真、恰当地行使了独立董事的职权，积极认真地出席了专门委 员会会议、董事会会议和股东大会，并充分发挥本人的经验和专长，在完善公司治理和 重大决策等方面做了许多工作，对有关事项发表了中肯、客观的意见，切实维护了公司 全体股东的利益。现将本人 2023 年度担任独立董事的履职情况报告如下： 一、独立董事的基本情况 （一）本人工作履历、专业背景以及兼职情况 本人刘曙萍，1970 年 1 月出生，中国国籍，无境外永久居留权，工商管理专业硕士。 2023 年 11 月至今上会会计师事务所（特殊普通合伙）湖南分所负责人；2013 年 10 月 至 2023 年 11 月，任大信会计师事务所(特殊普通合伙)长沙 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2024-046 湖南达嘉维康医药产业股份有限公司 关于召开 2023 年年度股东大会的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召集、召开符合《中华人民 共和国公司法》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2024 年 5 月 14 日（星期二）14:30 （2）公司董事、监事及高级管理人员； （3）公司聘请的律师； （2）网络投票时间：2024 年 5 月 14 日（星期二） 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 14 日 9:15-9:25、9:30-11:30，13:00-15:00；通过深圳交易所互联网投票系 统投票的具体时间为：2024 年 5 月 14 日 9:15—15:0 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2024- 036 湖南达嘉维康医药产业股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）第四届监事会第六 次会议于 2024 年 4 月 20 日在公司会议室以现场结合通讯的方式召开。会议通知 已于 2024 年 4 月 10 日通过邮件的方式送达全体监事。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席唐娟女士召集并主持。本次会议 的召集、召开和表决程序符合《中华人民共和国公司法》等有关法律、法规及规 范性文件和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真审议，形成如下决议： （一）审议通过《关于<2023 年度监事会工作报告>的议案》 2023 年度，公司监事会按照《公司法》《证券法》等法律法规以及《公司章 程》《监事会议事规则》等有关规定的要求，对公司股东大会和董事会等会议的 召集召开程序、公司经营活动、财务状况、重大决策及董事、高级管理人 ...

Financial Performance - The company's operating revenue for 2023 reached ¥3,903,503,781.52, representing an increase of 18.56% compared to ¥3,292,323,125.82 in 2022[17]. - The net profit attributable to shareholders of the listed company decreased by 32.85% to ¥34,299,844.15 from ¥51,119,784.99 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥34,322,553.37, down 26.69% from ¥46,860,490.33 in 2022[17]. - The net cash flow from operating activities improved significantly to ¥27,130,076.95, a 105.49% increase from a negative cash flow of ¥493,964,014.75 in the previous year[17]. - The total assets of the company increased by 34.24% to ¥5,277,655,319.75 compared to ¥3,931,417,218.63 at the end of 2022[18]. - The net assets attributable to shareholders of the listed company rose by 1.45% to ¥1,747,230,887.13 from ¥1,723,242,970.64 at the end of 2022[18]. - The basic earnings per share decreased by 32.00% to ¥0.17 from ¥0.25 in the previous year[17]. - The diluted earnings per share also fell by 32.00% to ¥0.17 from ¥0.25 in 2022[17]. - The weighted average return on net assets was 1.98%, down from 3.01% in the previous year[18]. Dividend Distribution - The company plans to distribute a cash dividend of 0.4 RMB per 10 shares to all shareholders, based on a total of 206,505,700 shares[3]. - The cash dividend distribution represents 100% of the total profit distribution amount[178]. - The profit distribution plan includes a cash dividend of CNY 0.40 per 10 shares, totaling CNY 8,260,228.00 to be distributed to shareholders[182]. Market Trends and Growth - The total sales of the national pharmaceutical circulation market reached ¥275.16 billion in 2022, with a year-on-year growth of 6.0%[27]. - The number of retail pharmacies in China increased from 454,000 in 2017 to 623,300 in 2022, reflecting a growing market[33]. - The chain rate of retail pharmacies rose from 50.44% in 2017 to 57.76% in 2022, indicating increasing market concentration[33]. - The top 100 chain stores accounted for 49% of the revenue in 2022, up 3 percentage points from 2021, showing a trend towards market consolidation[33]. Revenue Breakdown - The distribution business generated revenue of CNY 2,301.14 million, accounting for 58.95% of total revenue, with a year-on-year growth of 1.11%[37]. - The retail business reported revenue of CNY 1,505.31 million, representing a significant increase of 51.53% compared to the previous year, and accounted for 38.56% of total revenue[41]. - The DTP specialty pharmacy sales reached CNY 832.48 million, a growth of 14.43% year-on-year, with 450 product varieties sold[40]. - The pharmaceutical industrial segment generated revenue of CNY 75.85 million, making up 1.94% of total revenue[42]. - The medical services segment, through the subsidiary Jiachen Hospital, reported revenue of CNY 12.77 million, a 35.12% increase year-on-year[43]. Acquisitions and Investments - The company completed the acquisition of Hunan Tianji Caotang Pharmaceutical Co., Ltd. for ¥398,003,400, achieving a 99.9899% ownership stake[82]. - The acquisition of Yinchuan Meihotai Pharmaceutical Chain Co., Ltd. was completed for ¥250,800,000, resulting in 100% ownership[82]. - The company is currently working on several major R&D projects, including the approval of Oseltamivir Phosphate Syrup, which is expected to enhance future performance if approved[64]. - The company is in the process of acquiring a 51% stake in Shanxi Simail Drug Chain Co., Ltd. for ¥326,001,022, which is yet to be completed[83]. Research and Development - Research and development expenses surged by 1,268.85% to CNY 7,173,235.40, attributed to follow-up investments in newly acquired enterprises[63]. - The R&D investment as a percentage of operating income was 0.18% in 2023, up from 0.02% in 2022[64]. - The number of R&D personnel decreased by 50% from 38 in 2022 to 19 in 2023, impacting the company's R&D capacity[64]. - The company plans to enhance its core competitiveness through the integration of R&D personnel from newly acquired production enterprises[65]. Corporate Governance - The governance structure complies with the requirements set by the China Securities Regulatory Commission[119]. - The board consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[122]. - The company has established a performance evaluation and incentive mechanism for its directors and senior management[124]. - The company strictly adheres to information disclosure obligations, ensuring equal access to information for all shareholders[125]. - The company actively manages investor relations through various communication channels[126]. Environmental Compliance - Hunan Tianji Caotang Pharmaceutical Co., Ltd. is listed as a key pollutant discharge unit for 2023, adhering to multiple environmental protection laws and standards[193]. - The company incurs an annual operational cost of 510,000 RMB for wastewater treatment and pays an environmental protection tax of 4,515.10 RMB for 2023[200]. - The company has implemented a comprehensive environmental monitoring plan, with various pollutants monitored semi-annually and annually[198]. - The company has no instances of exceeding pollutant discharge limits in its operations[196]. Employee Management - The total number of employees at the end of the reporting period was 3,461, including 548 at the parent company and 2,913 at major subsidiaries[168]. - The company has established a salary system based on a combination of ability and contribution, with performance pay directly linked to individual output[170]. - The company provides various employee benefits, including pension, medical, unemployment, work injury, maternity insurance, and housing fund[171]. - The company has implemented a training program to enhance employee skills and integrate new members into the company culture[172].

湖南达嘉维康医药产业股份有限公司 2023 年度独立董事述职报告 （陆银娣） 本人作为湖南达嘉维康医药产业股份有限公司（以下简称"公司"）的独立 董事，在 2023 年 1 月 1 日至 2023 年 10 月 9 日担任公司独立董事期间，严格按 照《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板 股票上市规则》《公司章程》《独立董事工作制度》的规定，忠实、勤勉地履行了 独立董事的职责，谨慎、认真、恰当地行使了独立董事的职权，积极认真地出席 了专门委员会会议、董事会会议和股东大会，并充分发挥本人的经验和专长，在 完善公司治理和重大决策等方面做了许多工作，对有关事项发表了中肯、客观的 意见，切实维护了公司全体股东的利益。现将本人 2023 年度担任独立董事的履 职情况报告如下： 一、独立董事的基本情况 （一）本人工作履历、专业背景以及兼职情况 本人陆银娣，1962 年 1 月出生，中国国籍，无境外永久居留权，法国 INSEAD 商学院 EMBA。曾就职于美国礼来制药中国亚洲公司全国高级商务总监；苏州 礼来贸易有限公 ...

湖南达嘉维康医药产业股份有限公司 董事会审计委员会对会计师事务所 2023 年度履职情况评估 及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》和湖南达嘉维康医药 产业股份有限公司（以下简称"公司"）的《公司章程》《董事会审计委员会工作 细则》等规定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真 履职。现将董事会审计委员会对会计师事务所 2023 年度履职评估及履行监督职 责的情况汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 名称：天健会计师事务所（特殊普通合伙）（以下简称"天健会计师事务所"） 成立日期：2011 年 7 月 18 日 组织形式：特殊普通合伙 注册地址：浙江省杭州市西湖区灵隐街道西溪路 128 号 首席合伙人：王国海 截至 2023 年 12 月 31 日，天健会计师事务所合伙人（股东）238 人，注册 会计师 2,272 人。签署过证券服务业务审计报告的注册会计师人数超过 836 人。 天健会计师事务所 2023 年度业务收入为 34.83 亿元， ...

湖南达嘉维康医药产业股份有限公司 2023 年度监事会工作报告 2023 年度，湖南达嘉维康医药产业股份有限公司（以下简称"公司"）监 事会依照《公司法》《证券法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律 法规及和《公司章程》《监事会议事规则》的有关规定，本着对全体股东负责的 精神，依法独立行使职权，积极有效开展工作，对公司规范运作情况、财务情况、 公司董事和高级管理人员履行职责的情况进行监督，维护公司及股东的合法权益。 现将监事会 2023 年度的主要工作报告如下： 一、2023 年度监事会会议召开情况 2023 年度，公司监事会共召开了 10 次会议，会议的召集、召开及表决程序 符合《公司法》和《公司章程》的规定，具体情况及决议内容如下： | 会议届次 | 召开日期 | 会议决议 | | --- | --- | --- | | | 2023 年 4 月 20 日 | 审议通过： | | | | 1、关于《2022 年度监事会工作报告》的议案； | | | | 2、关于《2022 年度财务决算报告》的议案； | | 第三届监事会 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2024-041 湖南达嘉维康医药产业股份有限公司 组织形式：特殊普通合伙 注册地址：浙江省杭州市西湖区灵隐街道西溪路 128 号 首席合伙人：王国海 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）于 2024 年 4 月 20 日召开第四届董事会第七次会议，审议通过了《关于续聘会计师事务所的议 案》，同意续聘天健会计师事务所（特殊普通合伙）（以下简称"天健会计师事 务所"）为公司 2024 年度审计机构。本议案尚需提交股东大会审议。现将具体 情况公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1. 基本信息 名称：天健会计师事务所（特殊普通合伙） 成立日期：2011 年 7 月 18 日 截至 2023 年 12 月 31 日，天健会计师事务所合伙人（股东）238 人，注册 会计师 2,272 人。签署过证券服务业务审计报告的注册会计师人数超过 836 人。 天健会计师事务所 2023 年度业务收入为 34.8 ...